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Abstract
Hepatitis B virus (HBV) infection causes a spectrum of  
acute and chronic liver disease, ranging from inactive 
chronic carrier status to progressive chronic hepatitis, 
leading to end-stage cirrhosis and primary liver cancer. 
In sub-Saharan Africa, over 8% of  the population has 
chronic HBV carriage with a high risk for progressive liver 
disease. HBV-related hepatocellular carcinoma is the most 
common cancer among men and third most common 
among women. HBV therefore represents a critical threat 
to health in the African continent.  
Overview
In this article, we outline the state of  HBV prevalence, 
screening and management in sub-Saharan Africa (SSA). 
We highlight the urgent need for greater international 
support to improve local infrastructure for effective 
prevention and clinical management strategies for HBV 
infection.
Hepatitis B virus (HBV) infection causes a spectrum of  
acute and chronic liver disease, ranging from inactive 
chronic carrier status to progressive chronic hepatitis, 
leading to end-stage cirrhosis and liver cancer [1EASL 
2012]. Over one third of  the world’s population has been, 
or is currently infected with, HBV and 350-400 million 
people remain chronic HBV surface antigen (HBsAg) 
carriers [1]. There are over 500-750,000 reported deaths 
annually due to HBV-related cirrhosis and primary liver 
cancer worldwide. However, this figure underestimates 
the true HBV mortality rate due to inadequate disease 
and cancer surveillance in many resource-poor countries 
where HBV is endemic [2].
Within SSA, HBV infection is endemic and the HBV-
related disease burden is high. The lifetime risk of  
HBV infection is over 60% and more than 8% of  the 
population remain chronic HBV carriers who are at risk 
of  progressive liver disease and hepatocellular carcinoma 
(HCC).  HCC is a highly aggressive cancer with limited 
treatment options, particularly in resource-poor settings 
[3]. SSA has one of  the highest HBV-related liver cancer 
rates in the world [4], with HBV-related liver cancer 
the most common cancer among males and third most 
common cancer among females [5, 6 ]. Furthermore, the 
average age of  HCC development in Africa is considerably 
younger than in other parts of  the world (mean age 33 
years compared with 50 years in Asia and 60 years in 
Western Europe [9], meaning HBV-related HCC affects 
patients in their working and reproductive years [10 ]. 
HBV therefore represents a critical threat to health in the 
African continent.  
Treatment
Early detection and treatment of  HBV infection reduces 
HCC incidence and mortality (primary prevention) [11, 
12]. Furthermore, HCC survival is improved by early 
detection of  potentially treatable HCC by screening of  at-
risk patients (secondary prevention)[13]. However, access 
to medical care and the cost of  screening, diagnosis and 
treatment of  viral hepatitis and HCC are major limiting 
factors in hepatitis and liver cancer management in 
SSA. Routine HBV screening and surveillance programs 
for the general population are virtually non-existent in 
SSA and most nations lack the laboratory and medical 
infrastructure to implement such screening. A minority of  
countries in SSA offers free HBV screening of  pregnant 
mothers, healthcare workers and HIV-infected individuals. 
However, there is a lack of  infrastructure to support 
channeling of  screened patients into long-term treatment 
programs [14].
Safe and effective treatments for HBV exist, but treatment 
access is severely limited in SSA. The recent WHO 
Global Policy Report on the Prevention and Control 
of  Viral Hepatitis reported that only 16.7% of  WHO-
AFRO countries have publicly funded HBV treatment 
available, despite highly effective nucleoside analogues, 
such as tenofovir being available in most countries in 
SSA at generic price for the treatment of  HIV [14]. This 
staggering lack of  accessibility to affordable, effective 
HBV treatments needs addressing urgently if  any gains 
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are to be made in controlling the costly disease burden of  
HBV-related liver disease and HCC.
Control
Vaccination is the cornerstone of  HBV prevention and is 
most effective when given within 24 hours of  birth [15, 16]. 
Multiple studies from SSA have demonstrated that HBV 
vaccination of  infants is both feasible and highly effective 
for preventing chronic HBV carriage and HCC [17, 18, 
19]. Despite WHO guidelines recommending that HBV 
vaccination should be given within 24 hours of  birth, the 
vaccine schedule of  6, 10 and 14 weeks has been adopted 
in most African countries to allow the use of  combination 
vaccines and to minimise costs and logistic expenses by 
streamlining vaccination schedules [20]. However, HBV 
vaccination coverage remains highly variable in SSA and 
there are little data on infant HBV vaccination coverage in 
South Sudan [21, 14].
Control of  HBV prevalence is a major goal for the World 
Health Organization (WHO) worldwide, with a key 
focus on HBV prevention in African countries. In 2010, 
the World Health Assembly (WHA) passed a resolution 
calling for public health intervention to prevent and 
control viral hepatitis. There is also a forthcoming WHA 
resolution requesting the Global Health Fund to provide 
antiviral medications for HBV mono-infected patients. 
HBV treatment that is accessible and affordable to all 
is a pressing requirement in SSA and greater support 
from the international medical community is critical to 
engender support from the pharmaceutical industry for 
equitable drug availability. Greater support for medical 
service infrastructure and staff  education is paramount 
to assist countries in SSA to develop and sustain essential 
HBV research platforms and public health intervention 
campaigns. African and international medical associations 
for liver disease and infectious diseases, community hepatitis 
groups and healthcare workers need to band together to 
forge a path for the education and promotion of  viral 
hepatitis among all levels of  the African community. The 
crucial importance of  viral hepatitis research, treatment 
and prevention campaigns is more likely to be heard by 
pharmaceutical industry and government policy makers 
when delivered by a strong united voice.
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A 34-year old male presented with a 3-months history of  
anorexia, weight loss and rectal bleeding. There was a strong 
family history of  several members with colorectal cancer. 
Examination was unremarkable except for generalized 
muscle wasting. Investigations revealed anaemia and a 
positive faecal blood test. Colonoscopy showed an ulcero-
proliferative growth involving the proximal descending colon 
causing significant luminal narrowing. Biopsy was consistent 
with adenocarcinoma colon. At endoscopy distal colon also 
revealed the appearance as in Figure 1.
Figure 1. Endoscopy of  distal colon
Questions
Q1. What is the endoscopy finding in Figure 1?
Q2. What is the most probable diagnosis?
Q3. What is the genetic abnormality involved?
Q4. What are the variants?
Q5. Name the associated extra-gastrointestinal neoplasms.
Q6. What is the treatment?  
